The Longevity Biotech Fellowship helps our members build, join, or invest in revolutionary longevity biotechnology projects.
We operate as an IRS-approved 501(c)3 non-profit -- registered under LessDeath Inc -- based in Santa Clara, California.
Read more about LessDeath's structure and charitable status, here.
.png)
We celebrate the wins of all people working to expand the boundless frontier of healthy human lifespan.
We believe that longevity is the ultimate purpose of technology and the highest leverage fulcrum to reduce suffering.
It is our duty and joy to serve the longevity community in order to accelerate growth and speed up development of aging interventions.
Mark’s career has progressed from manual bench work in academia, to lab automation at Synthego, to longevity movement building - always seeking better methods and higher leverage ways to accelerate progress.
.png)
Nathan is a physics PhD dropout who made the jump to longevity, first by writing the most read longevity investing newsletter, then founding the ODLB community and Healthspan Capital - he wants to inspire others to make the similar leaps.
Experienced as a scientist, entrepreneur and VC Partner at IndieBio. Jun enjoys applying her multifaceted perspective to advising and inspiring people on how to achieve their goals and build a better future.
Dr. O’Connor has Ph.D. in Biochemistry from Baylor College of Medicine. His postdoctoral research included work at UC Berkeley on muscle stem cells and aging. He is the former VP of Research at SENS Research Foundation and is currently the CEO of Cyclarity Therapeutics.
Roland is building the European LBF community with his insights from ontology and the shamanic world. He is early in his career and transitioned from tech startups to clinical research.
Cat has a background in software engineering and venture capital. She is a core member at VitaDAO and ran the Longevity Zero to One course at Zuzalu. Now, she's working to build the LBF Longevity Course.
Sean is a communication generalist with experience in biology and policy. He’s been hardwiring his life for ending aging since age 17. He most recently worked at the Alliance for Longevity Initiatives to establish the Longevity Science Caucus in Congress.
Dr. Florea completed his PhD at Harvard Medical School in 2023 with a focus on gene delivery technology. He is the CEO and co-founder of a stealth longevity techbio co. Amongst many other side projects, he is the team lead for the LBF Bottlenecks to Progress community project.
